Lightnews — Scholar-powered news

Reposted by Jennifer Juno

Angie Rasmussen @angierasmussen.bsky.social · Sep 8

I am always so impressed by @marioskoutsakos.viralvaxlab.com’s elegant work on influenza B virus vaccines. Congratulations, Marios, on your Early Career Researcher Award! #19vaccinecongress

1 4 54

Reposted by Jennifer Juno

Dr Elissa Deenick @elissadeenick.bsky.social · Jul 9

The Precision Immunology and Immune Biotherapies Programs at the Garvan Institute are looking for new Faculty members. Come join us and work with amazing scientists in an amazing place @labphan.bsky.social @garvaninstitute.bsky.social
www.nature.com/naturecareer...

Garvan Faculty Member - Sydney (LGA), New South Wales (AU) job with The Garvan Institute | 12841341

The Garvan Institute invites applicants for Faculty-level positions in the Immune Biotherapies and Precision Immunology Programs.

www.nature.com

4 8

Reposted by Jennifer Juno

Dr. Dawn Bowdish @msmacrophage.bsky.social · Jun 6

Publication alert: "No evidence of immune exhaustion after repeated SARS-CoV-2 vaccination in vulnerable and healthy populations" ‪@natcomms.nature.com‬ The backstory is particularly interesting-it's a tale of the conflicting needs of scientists & decision makers in times of disinformation ....1/n

No evidence of immune exhaustion after repeated SARS-CoV-2 vaccination in vulnerable and healthy populations

Nature Communications - Repeated vaccination is needed to maintain high levels of SARS-CoV-2 immunity in vulnerable populations, but there is concern that it could lead to immune exhaustion. Here,...

rdcu.be

4 39 98

Reposted by Jennifer Juno

Joanna Groom @groomlab.bsky.social · May 8

Excited to have our latest research published in @jem.org this week and also highlighted by @natrevimmunol.nature.com
@wehi-research.bsky.social @benjbroom.bsky.social

7 31

Jennifer Juno @jenjuno.viralvaxlab.com · Apr 29

Fantastic work from @labphan.bsky.social and @mlmunier.bsky.social combining mouse models and clinical studies to understand B cell recall following booster vaccination. Check out the paper and thread below! ⤵️

IMAGE Lab @labphan.bsky.social · Apr 29

Happy #DayofImmunology! Congrats @ramadhenni.bsky.social & Alexandra Carey Hoppé it's out (finally!) @cp-cell.bsky.social! Incredibly grateful to co-leads @mlmunier.bsky.social, Vanessa Venturi & Tony Kelleher & all brilliant folks @garvaninstitute.bsky.social & Kirby Inst. for fantastic collab! 🧵

Macrophages direct location-dependent recall of B cell memory to vaccination

Vaccines generate long-lived plasma cells and memory B cells (Bmems) that may re-enter secondary germinal centers (GCs) to further mutate their B cell…

www.sciencedirect.com

1 5

Jennifer Juno @jenjuno.viralvaxlab.com · Apr 27

Happy to report that Mitchell's paper on CD4 T cells and AIM assays is now available online at Science Advances!

www.science.org/doi/10.1126/...

Thanks to all our collaborators in @viralvaxlab.bsky.social and @thedohertyinst.bsky.social, including @assocprofashhaque.bsky.social lab

6 16

Jennifer Juno @jenjuno.viralvaxlab.com · Apr 25

Check out the latest from @viralvaxlab.bsky.social postdoc Wen Shi Lee, developing monoclonal antibodies that neutralise the NL63 coronavirus!

Thelonevirologist @thelonevirologist.bsky.social · Apr 25

Potent neutralising monoclonal antibodies targeting the spike of NL63 coronavirus

www.nature.com/articles/s44...

Potent neutralising monoclonal antibodies targeting the spike of NL63 coronavirus - npj Viruses

npj Viruses - Potent neutralising monoclonal antibodies targeting the spike of NL63 coronavirus

www.nature.com

3 7

Jennifer Juno @jenjuno.viralvaxlab.com · Apr 4

Great new story exploring how B cells can recognise glycans (and still get T cell help!) from @precisionvaxlab.bsky.social and team!

Dr Danika Hill @precisionvaxlab.bsky.social · Apr 4

New preprint alert 🚨

My team and I are pleased to share our most recent story about how bacterial pathogen (Streptococcus pyogenes, Strep A) exposure induces antibody responses against glycan and protein antigens.

For paper: SSRN ssrn.com/abstract=519...
biorxiv : doi: doi.org/10.1101/2025...

1 8

Jennifer Juno @jenjuno.viralvaxlab.com · Mar 20

What do you need them for, Julie? We might have other lines that would work for your experiments.

1

Reposted by Jennifer Juno

The American Association of Immunologists @aai.org · Mar 13

New research in @jimmunol.bsky.social from @jenjuno.viralvaxlab.com and Dr. Hyon-Xhi Tan suggests that receiving multiple doses of a vaccine in the same limb leads to faster antibody development. Learn more: news.aai.org/2025/03/10/m.... #medsky #immunosky #idsky

Multi-Dose Vaccines Administered in the Same Site Boost Immune Response - AAI News

New research suggests that receiving multiple doses of a vaccine in the same limb leads to faster antibody development.

news.aai.org

4 7

Jennifer Juno @jenjuno.viralvaxlab.com · Mar 11

Check out the latest work from @viralvaxlab.bsky.social, now online in @jimmunol.bsky.social!

The Journal of Immunology @jimmunol.bsky.social · Mar 10

New research from @thedohertyinst.bsky.social suggests that receiving multiple doses of a vaccine in the same limb leads to faster antibody development, an important strategy for providing #immunity quickly during a pandemic or disease #outbreak. #ReadTheJI #immunology

ow.ly/c28N50VeRGR

Modulation of germinal center and antibody dynamics via ipsilateral versus contralateral immunization against SARS-CoV-2

Abstract. Human clinical trials have reported immunological outcomes can differ between ipsilateral (same side) and contralateral (alternate sides) prime-b

ow.ly

1 2

Reposted by Jennifer Juno

JCI insight @insight.jci.org · Feb 28

Should you get the COVID mRNA and flu vaccines in the same or opposite arms?

Randomised trial by Lee, Selva, et al. suggests it is preferable to administer the vaccines at different sites. buff.ly/3D4gX95

1 3 7

Jennifer Juno @jenjuno.viralvaxlab.com · Feb 28

Unfortunately, Melbourne isn't going to be quite as seamless of an experience...

1

Reposted by Jennifer Juno

Adrian Liston @labliston.bsky.social · Feb 3

If any American immunologists want to write an op-ed for @immunolcellbiol.bsky.social on the impact of the new executive orders, please contact me

1 9 13

Reposted by Jennifer Juno

Joanna Groom @groomlab.bsky.social · Jan 15

Kicking off the new year searching for a postdoc to join our team @wehi-research.bsky.social
Apply now and spread the word

Research Officer

Job Title Research Officer Job Description An excellent opportunity is available for a Research Officer to join the Groom Laboratory in the Immunology Division at Australia’s pre-eminent biomedical re...

wehi.wd3.myworkdayjobs.com

13 9

Jennifer Juno @jenjuno.viralvaxlab.com · Jan 10

Thanks Jo!

1

Jennifer Juno @jenjuno.viralvaxlab.com · Jan 10

Thanks Danika!

1

Jennifer Juno @jenjuno.viralvaxlab.com · Dec 20

9/9 Thanks to all our collaborators who helped out with the study, and congrats to Mitchell, who persevered through a lot of possible activation marker combinations!

1 4

Jennifer Juno @jenjuno.viralvaxlab.com · Dec 20

8/9 In short, we suggest in vitro stimulation activates ag-specific T cells, which secrete cytokines and activate Treg and Th17/22 cells. Without careful phenotyping, all of these cells can get picked up as AIM+, accounting for the Th17-like memory cells found in many virus-specific AIM datasets.

1 2 8

Jennifer Juno @jenjuno.viralvaxlab.com · Dec 20

7/9 Mitch sorted tetramer-specific cells, labelled them, and added them back into PBMC before stimulating with the relevant peptide.

He was able to show that ag-specific CD4 cells downregulate CXCR4 while upregulating 4-1BB/CD137, giving us a more accurate way to define antigen specificity.

1 2

Jennifer Juno @jenjuno.viralvaxlab.com · Dec 20

6/9 Unfortunately, these cytokine-activated cells upregulated almost all of the AIM markers we normally use.

One difference, however, appeared to be CXCR4. TCR-mediated activation efficiently downregulates CXCR4 expression, while cytokine-mediated activation has much less of an impact.

1 1

Jennifer Juno @jenjuno.viralvaxlab.com · Dec 20

5/9 Using RNAseq and confirmatory FACS, Mitch showed that CD39+ Tregs and Th17/Th22 cells expressing CCR6 and high levels of CD26 were being activated through the transwell via a mechanism involving IL-2.

These same subsets are also found during standard peptide-based AIM assays.

1 1

Jennifer Juno @jenjuno.viralvaxlab.com · Dec 20

4/9 Possibly!

In a transwell assay, anti-CD3/CD28 stimulation can drive T cells in an adjacent chamber to express common activation markers (CD25, OX-40, 4-1BB, CD40L).

All of these responding cells had a memory phenotype, and were strongly enriched for CCR6 expression.

1 1

Jennifer Juno @jenjuno.viralvaxlab.com · Dec 20

3/9 Mitch ruled out a few options: CD4 cells don’t upregulate CCR6 during peptide stimulation, and the AIM+ CCR6+ cells don’t usually contain clonally expanded TCRs.

Does that mean that AIM assays might be picking up cases of TCR-independent activation?

1 1

Jennifer Juno @jenjuno.viralvaxlab.com · Dec 20

2/9 Recently, though, we’ve been bothered by something we couldn’t explain: we find a lot of Th17-like, CCR6+ SARS-CoV-2 spike-specific CD4 T cells in our AIM assays, but we never see these cells when we use spike-specific class II tetramers.

Why?

1 1